This report describes and explains the global regenerative medicine for cartilage market and covers 2016 to 2021, termed the historic period, and 2021 to 2026 termed the forecast period, along with further forecasts for the period 2026 to 2031. The report evaluates the market across each region and for the major economies within each region.
The global regenerative medicine for cartilage market reached a value of nearly $3,779.4 million in 2021, having increased at a compound annual growth rate (CAGR) of 4.6% since 2016. The market is expected to grow from $3,779.4 million in 2021 to $5,017.3 million in 2026 at a rate of 5.8%. The market is then expected to grow at a CAGR of 6.0% from 2026 and reach $6,727.0 million in 2031.
Growth in the historic period in the regenerative medicine for cartilage market resulted from a rise in awareness and expenditure in healthcare, changes in lifestyles, ability to command high prices, strong economic growth in emerging markets, increase in insurance coverage, and rapid growth in elderly population. The market was restrained by stringent regulations from regulators, inadequate reimbursements, and low healthcare access.
Going forward, increasing prevalence of chronic diseases, rising geriatric population, technological advances, and a rise in healthcare expenditure are expected to be the major drivers of the matrket. Factors that could hinder the growth of the market in the future include rising popularity of alternative therapies and natural remedies, tissue-engineered products and biomaterials are lagging in adoption, and low per capita healthcare expenditure.
The regenerative medicine for cartilage market is segmented by treatment modality into cell-based, and non-cell-based. The cell-based segment was the largest segment of the regenerative medicine for cartilage market segmented by treatment modality, accounting for 91.2% of the total in 2021. Going forward, the non-cell-based segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by treatment modality, at a CAGR of 11.6% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by treatment type into palliative, intrinsic repair stimulus, and others. The palliative segment was the largest segment of the regenerative medicine for cartilage market segmented by treatment type, accounting for 38.3% of the total in 2021. Going forward, the palliative segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by treatment type, at a CAGR of 7.0% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by site into knee cartilage repair, ribs, and others. The knee cartilage repair segment was the largest segment of the regenerative medicine for cartilage market segmented by site, accounting for 47.6% of the total in 2021. Going forward, the ribs segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by site, at a CAGR of 6.4% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by application into hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration. The hyaline cartilage repair and regeneration segment was the largest segment of the regenerative medicine for cartilage market segmented by application, accounting for 62.5% of the total in 2021. Going forward, the hyaline cartilage repair and regeneration segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by application, at a CAGR of 6.1% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by end use into ambulatory surgical centers, hospitals & clinics, and others. The hospitals & clinics segment was the largest segment of the regenerative medicine for cartilage market segmented by end use, accounting for 66.8% of the total in 2021. Going forward, hospitals & clinics segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by end use, at a CAGR of 6.1% during 2021-2026.
North America was the largest region in the regenerative medicine for cartilage market, accounting for 52.4% of the total in 2021. It was followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the regenerative medicine for cartilage market will be Middle East and Africa where growth will be at CAGRs of 31.9% and 30.7% respectively during 2021-2026. These will be followed by Eastern Europe and Asia Pacific, where the markets are expected to register CAGRs of 23.8% and 22.1% respectively during 2021-2026.
COVID-19 is highly infectious and contagious in nature, for which the population is not pre-immune. Hence, diagnosis plays a critical role in such diseases. The number of people infected with the COVID-19 virus has been increasing significantly which calls for the need to shorten the time taken for diagnosis and treatment, better and accurate detection speeds, and the development of innovative molecular diagnostic techniques. The availability of efficient and accurate laboratory diagnosis is critical for the effective prevention and control of the pandemic. Early detection, diagnosis, isolation, and treatment is the most effective way to prevent and control COVID 19. The COVID-19 impacted the global regenerative medicine for cartilage market in the initial phase pandemic. Elective surgeries were cancelled or postponed to reserve the available limited capacities and resources such as hospital beds and healthcare professionals toward COVID-19 patient care. Moreover, to control the rising number of positive COVID-19 cases, several countries implemented lockdowns and curfews. Furthermore, patients were unable to visit hospitals, clinics, or OPDs due to the lockdowns. The cartilage repair and regeneration industries are projected to be hindered by the temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services.
The global regenerative medicine for cartilage market is fragmented, with a few large players constituting significant market share. The top ten competitors in the market made up to 24.69% of the total market in 2020. The market consolidation can be attributed to the high barriers to entry in terms of high costs associated with the production of regenerative medicine for cartilage. The market is expected to be concentrated state in near future with the adoption of acquisition and merger strategies by the players to enter and expand into newer geographies.
The top opportunities in the regenerative medicine for cartilage market segmented by treatment modality will arise in cell-based segment, which will gain $994.1 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by treatment type will arise in palliative segment, which will gain $577.9 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by site will arise in knee cartilage repair segment, which will gain $526.5 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by application will arise in hyaline cartilage repair and regeneration segment, which will gain $807.6 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by end use will arise in hospitals & clinics segment, which will gain $868.8 million of global annual sales by 2026. The regenerative medicine for cartilage market size will gain the most in the USA at $236.7 million.
Market-trend-based strategies for the regenerative medicine for cartilage include focus on entering into strategic collaborations and agreements to broaden their product portfolios, boost revenues and establish category leadership, companies should closely monitor advances in mesenchymal stem cell technology with a view to capitalizing on innovations in the field, modified cell therapy to optimize cartilage efficacy and increase therapeutic options, invest in biomaterial research to develop advanced cell-matrix technologies novel advanced Injectable hydrogels techniques to bring more advancements in this field, invest in the emerging science of bioactive signals, focus on investing in technology transfer and clinical translation to enable regenerative medicine research and development and consider collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.
Player-adopted strategies in the regenerative medicine for cartilage market includes strategic collaboration and acquisitions for research & development activities, investments, strategic partnerships for production new regenerative medicine for cartilage, and new product launches to meet the global demand and strengthen their product portfolio.
To take advantage of the opportunities, the publisher reccomends the regenerative medicine for cartilage companies to focus on growing use of mesenchymal stem cell technology in cartilage repair, focus on investing in technology transfer and clinical translation, invest in biomaterial research to develop novel advanced injectable hydrogels techniques, focus on growing research on bioactive signals, expand in countries that offer incentives, include bundled payments options, offer competitively priced products, participate in trade shows and events, build strategic relationships with large-scale end-users and target hospitals including pharmacies to spread awareness on stem cell therapy.
The global regenerative medicine for cartilage market reached a value of nearly $3,779.4 million in 2021, having increased at a compound annual growth rate (CAGR) of 4.6% since 2016. The market is expected to grow from $3,779.4 million in 2021 to $5,017.3 million in 2026 at a rate of 5.8%. The market is then expected to grow at a CAGR of 6.0% from 2026 and reach $6,727.0 million in 2031.
Growth in the historic period in the regenerative medicine for cartilage market resulted from a rise in awareness and expenditure in healthcare, changes in lifestyles, ability to command high prices, strong economic growth in emerging markets, increase in insurance coverage, and rapid growth in elderly population. The market was restrained by stringent regulations from regulators, inadequate reimbursements, and low healthcare access.
Going forward, increasing prevalence of chronic diseases, rising geriatric population, technological advances, and a rise in healthcare expenditure are expected to be the major drivers of the matrket. Factors that could hinder the growth of the market in the future include rising popularity of alternative therapies and natural remedies, tissue-engineered products and biomaterials are lagging in adoption, and low per capita healthcare expenditure.
The regenerative medicine for cartilage market is segmented by treatment modality into cell-based, and non-cell-based. The cell-based segment was the largest segment of the regenerative medicine for cartilage market segmented by treatment modality, accounting for 91.2% of the total in 2021. Going forward, the non-cell-based segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by treatment modality, at a CAGR of 11.6% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by treatment type into palliative, intrinsic repair stimulus, and others. The palliative segment was the largest segment of the regenerative medicine for cartilage market segmented by treatment type, accounting for 38.3% of the total in 2021. Going forward, the palliative segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by treatment type, at a CAGR of 7.0% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by site into knee cartilage repair, ribs, and others. The knee cartilage repair segment was the largest segment of the regenerative medicine for cartilage market segmented by site, accounting for 47.6% of the total in 2021. Going forward, the ribs segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by site, at a CAGR of 6.4% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by application into hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration. The hyaline cartilage repair and regeneration segment was the largest segment of the regenerative medicine for cartilage market segmented by application, accounting for 62.5% of the total in 2021. Going forward, the hyaline cartilage repair and regeneration segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by application, at a CAGR of 6.1% during 2021-2026.
The regenerative medicine for cartilage market is also segmented by end use into ambulatory surgical centers, hospitals & clinics, and others. The hospitals & clinics segment was the largest segment of the regenerative medicine for cartilage market segmented by end use, accounting for 66.8% of the total in 2021. Going forward, hospitals & clinics segment is expected to be the fastest growing segment in the regenerative medicine for cartilage market segmented by end use, at a CAGR of 6.1% during 2021-2026.
North America was the largest region in the regenerative medicine for cartilage market, accounting for 52.4% of the total in 2021. It was followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the regenerative medicine for cartilage market will be Middle East and Africa where growth will be at CAGRs of 31.9% and 30.7% respectively during 2021-2026. These will be followed by Eastern Europe and Asia Pacific, where the markets are expected to register CAGRs of 23.8% and 22.1% respectively during 2021-2026.
COVID-19 is highly infectious and contagious in nature, for which the population is not pre-immune. Hence, diagnosis plays a critical role in such diseases. The number of people infected with the COVID-19 virus has been increasing significantly which calls for the need to shorten the time taken for diagnosis and treatment, better and accurate detection speeds, and the development of innovative molecular diagnostic techniques. The availability of efficient and accurate laboratory diagnosis is critical for the effective prevention and control of the pandemic. Early detection, diagnosis, isolation, and treatment is the most effective way to prevent and control COVID 19. The COVID-19 impacted the global regenerative medicine for cartilage market in the initial phase pandemic. Elective surgeries were cancelled or postponed to reserve the available limited capacities and resources such as hospital beds and healthcare professionals toward COVID-19 patient care. Moreover, to control the rising number of positive COVID-19 cases, several countries implemented lockdowns and curfews. Furthermore, patients were unable to visit hospitals, clinics, or OPDs due to the lockdowns. The cartilage repair and regeneration industries are projected to be hindered by the temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services.
The global regenerative medicine for cartilage market is fragmented, with a few large players constituting significant market share. The top ten competitors in the market made up to 24.69% of the total market in 2020. The market consolidation can be attributed to the high barriers to entry in terms of high costs associated with the production of regenerative medicine for cartilage. The market is expected to be concentrated state in near future with the adoption of acquisition and merger strategies by the players to enter and expand into newer geographies.
The top opportunities in the regenerative medicine for cartilage market segmented by treatment modality will arise in cell-based segment, which will gain $994.1 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by treatment type will arise in palliative segment, which will gain $577.9 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by site will arise in knee cartilage repair segment, which will gain $526.5 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by application will arise in hyaline cartilage repair and regeneration segment, which will gain $807.6 million of global annual sales by 2026. The top opportunities in the regenerative medicine for cartilage market segmented by end use will arise in hospitals & clinics segment, which will gain $868.8 million of global annual sales by 2026. The regenerative medicine for cartilage market size will gain the most in the USA at $236.7 million.
Market-trend-based strategies for the regenerative medicine for cartilage include focus on entering into strategic collaborations and agreements to broaden their product portfolios, boost revenues and establish category leadership, companies should closely monitor advances in mesenchymal stem cell technology with a view to capitalizing on innovations in the field, modified cell therapy to optimize cartilage efficacy and increase therapeutic options, invest in biomaterial research to develop advanced cell-matrix technologies novel advanced Injectable hydrogels techniques to bring more advancements in this field, invest in the emerging science of bioactive signals, focus on investing in technology transfer and clinical translation to enable regenerative medicine research and development and consider collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.
Player-adopted strategies in the regenerative medicine for cartilage market includes strategic collaboration and acquisitions for research & development activities, investments, strategic partnerships for production new regenerative medicine for cartilage, and new product launches to meet the global demand and strengthen their product portfolio.
To take advantage of the opportunities, the publisher reccomends the regenerative medicine for cartilage companies to focus on growing use of mesenchymal stem cell technology in cartilage repair, focus on investing in technology transfer and clinical translation, invest in biomaterial research to develop novel advanced injectable hydrogels techniques, focus on growing research on bioactive signals, expand in countries that offer incentives, include bundled payments options, offer competitively priced products, participate in trade shows and events, build strategic relationships with large-scale end-users and target hospitals including pharmacies to spread awareness on stem cell therapy.
Table of Contents
1. Regenerative Medicine For Cartilage Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. Regenerative Medicine For Cartilage Market Characteristics
8. Regenerative Medicine For Cartilage Market Trends And Strategies
9. Impact Of COVID-19 On Regenerative Medicine For Cartilage
10. Global Regenerative Medicine For Cartilage Market Size And Growth
11. Global Regenerative Medicine For Cartilage Market Segmentation
12. Regenerative Medicine For Cartilage Market, Regional And Country Analysis
13. Asia-Pacific Regenerative Medicine For Cartilage Market
14. Western Europe Regenerative Medicine For Cartilage Market
15. Eastern Europe Regenerative Medicine For Cartilage Market
16. North America Regenerative Medicine For Cartilage Market
17. South America Regenerative Medicine For Cartilage Market
18. Middle East Regenerative Medicine For Cartilage Market
19. Africa Regenerative Medicine For Cartilage Market
20. Regenerative Medicine For Cartilage Market Competitive Landscape
21. Key Mergers And Acquisitions In The Regenerative Medicine For Cartilage Market
22. Regenerative Medicine For Cartilage Market Opportunities And Strategies
23. Regenerative Medicine For Cartilage Market, Conclusions And Recommendations
24. Appendix
Executive Summary
Regenerative Medicine For Cartilage Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global regenerative medicine for cartilage market as it emerges from the COVID 19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Description:
Where is the largest and fastest growing market for regenerative medicine for cartilage? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The Regenerative Medicine for Cartilage global report answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider regenerative medicine for cartilage; and compares it with other markets.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives a brief introduction about segmentation by geography, segmentation by treatment modality, segmentation by treatment type, segmentation by site, segmentation by application and segmentation by end-user.
- Market Characteristics - The market characteristics section of the report defines and explains the regenerative medicine for cartilage market. This chapter also defines and describes goods and related services covered in the report.
- Trends And Strategies - This chapter describes the major trends shaping the global regenerative medicine for cartilage market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the regenerative medicine for cartilage market.
- Global Market Size And Growth - This section contains the global historic (2016-2021) and forecast (2021-2026) and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2016-2031) and analysis for different segments.
- Global Macro Comparison - The global regenerative medicine for cartilage market comparison with macro-economic factors gives the regenerative medicine for cartilage market size, percentage of GDP, and average regenerative medicine for cartilage market expenditure.
- Regional Market Size and Growth - This section contains the region’s market size (2021), historic (2016-2021) and forecast (2021-2026) and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa, and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global regenerative medicine for cartilage market, estimated market shares, and company profiles for the leading players.
- Key Mergers And Acquisitions - This chapter gives information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - This section includes conclusions and recommendations based on the findings of the research. This section gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is the significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for regenerative medicine for cartilage providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS (North American Industry Classification System) codes covered, abbreviations, and currencies codes used in this report.
Scope
Markets Covered:
- 1) By Treatment Modality: Cell-Based; Non-Cell-Based
- 2) By Treatment Type: Palliative; Intrinsic Repair Stimulus; Others Skin Resurfacing
- 3) By Site: Knee Cartilage Repair; Ribs; Others
- 4) By Application: Hyaline Cartilage Repair and Regeneration; Elastic Cartilage Repair and Regeneration; Fibrous Cartilage Repair and Regeneration.
- 5) By End-User: Ambulatory Surgical Centers; Hospitals & Clinics; Others
Companies Mentioned:
Smith & Nephew plc; Stryker Corporation; Zimmer Biomet Holdings Inc.; B. Braun Melsungen AG; Arthrex Inc.
Countries:
China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; regenerative medicine for cartilage indicators comparison.
Data segmentations:
country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Smith & Nephew plc
- Stryker Corporation
- Zimmer Biomet Holdings Inc.
- B. Braun Melsungen AG
- Arthrex Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 276 |
| Published | July 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 3779.4 Million |
| Forecasted Market Value ( USD | $ 6727 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
